研究单位：[1]Peking University First Hospital[2]Sinocelltech Ltd.[3]Anhui Provincial Hospital,Hefei,Anhui,China,230001[4]Peking University First Hospital,Beijing,China,100034[5]Beijing Tongren Hospital, CMU,Beijing,China,100176[6]PetroChina Central Hospital,Langfang,Hebei,China,050011[7]Hunan Provincial Center for Disease Control And Prevention,Changsha,Hunan,China,410005
研究目的：
SCTV01C-02-1 is a randomized, double-blind, placebo controlled Phase Ⅰ/Ⅱ clinical trial of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant bivalent trimeric S protein vaccine manufactured by Sinocelltech, Ltd. The purpose of this study is to evaluate the safety , tolerability and immunogenicity of the experimental vaccine in healthy adults aged ≥ 18 Years previously unvaccinated.
